Evidence map›Paper›PMID 26346982›Full record

ArticleBMC complementary and alternative medicine2015

Calycosin-7-O-β-D-glucoside promotes oxidative stress-induced cytoskeleton reorganization through integrin-linked kinase signaling pathway in vascular endothelial cells.

Yue-Hua Jiang, Wei Sun, Wei Li, Hong-Zhen Hu, Le Zhou, Hui-Hui Jiang, Jing-Xin Xu

RetractedOpen access · hybridAbstract readRetracted Publication
In one paragraph

Article in BMC complementary and alternative medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.0field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Frontiers in pharmacology · 2021
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Yak-Kong Soybean (Nutrients · 2019
    Article
  9. Article
  10. Calycosin-7-Neural plasticity · 2019
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Yue-Hua JiangAffiliated Hospital of Shandong University of Traditional Chinese Medicine, West Wenhua road #42, Jinan, Shandong, 250011, PR China. jiang_yuehua@hotmail.com.
Wei SunJiangsu Province Hospital of Traditional Chinese Medicine, Nanjing, 210029, China. jssunwei@163.com.
Wei LiAffiliated Hospital of Shandong University of Traditional Chinese Medicine, West Wenhua road #42, Jinan, Shandong, 250011, PR China. lweidw@163.com.
Hong-Zhen HuAffiliated Hospital of Shandong University of Traditional Chinese Medicine, West Wenhua road #42, Jinan, Shandong, 250011, PR China. hhzhen969@163.com.
Le ZhouAffiliated Hospital of Shandong University of Traditional Chinese Medicine, West Wenhua road #42, Jinan, Shandong, 250011, PR China. zhoule1221@163.com.
Hui-Hui JiangAffiliated Hospital of Shandong University of Traditional Chinese Medicine, West Wenhua road #42, Jinan, Shandong, 250011, PR China. jianghh@163.com.
Jing-Xin XuAffiliated Hospital of Shandong University of Traditional Chinese Medicine, West Wenhua road #42, Jinan, Shandong, 250011, PR China. 1289791127@qq.com.
Shandong University of Traditional Chinese Medicine · CNNanjing Traditional Chinese Medicine Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDysfunction of vascular endothelium is implicated in many pathological situations. Cytoskeleton plays an importance role in vascular endothelial permeability barrier and inflammatory response. Many Chinese herbs have the endothelial protective effect, of which, "Astragalus membranaceus" is a highly valued herb for treatment of cardiovascular and renal diseases in traditional Chinese medicine, In this study, we tested whether calycosin-7-O-β-D-glucoside (Calycosin), a main effective monomer component of "Astragalus membranaceus", could protect endothelial cells from bacterial endotoxin (LPS)-induced cell injury.

methodsEndothelial cell injury was induced by exposing human umbilical vein endothelial cells (HUVECs) to LPS. The effects of calycosin on LPS-induced changes in cell viability, apoptosis rate, cell migration, nitric oxide synthase (NOS), generationof intracellular reactive oxygen species (ROS) and cytoskeleton organization were determined. Microarray assay was employed to screen the possible gene expression change. Based on the results of microarray assay, the expression profile of genes involved in Rho/ROCK pathway and AKT pathway were further evaluated with quantitative real-time RT-PCR or western blot methods.

resultsCalycosin improved cell viability, suppressed apoptosis and protected the cells from LPS-induced reduction in cell migration and generation of ROS, protein level of NOS at a comparable magnitude to that of Y27632 and valsartan. Similar to Y27632 and valsartan, Calycosin, also neutralized LPS-induced actomyosin contraction and vinculin protein aggregation. Microarray assay, real-time PCR and western blot results revealed that LPS induced expression of FN, ITG A5, RhoA, PI3K (or PIP2 in western blotting), FAK, VEGF and VEGF R2, and inhibited expression of MLCP. We believed multiple pathways involved in the regulation of calycosin on HUVECs. Calycosin are considered to be able to activate MLCP through promoting the generation of NO, decreasing PMLC, suppressing the cytoskeleton remodeling caused by activation of Rho/ROCK pathway and inhibiting AKT pathway by decreasing VEGF, VEGF R2 and PI3K level.

conclusionCalycosin protected HUVEC from LPS-induced endothelial injury, possibly through suppression of Rho/ROCK pathway and regulation of AKT pathway.

Indexed as

Cells, CulturedCytoskeletonGlucosidesHumansHuman Umbilical Vein Endothelial CellsIsoflavonesOxidative StressProtein Serine-Threonine KinasesScaffold Protein ILKSignal Transductioncalycosin-7-O-beta-D-glucosideGlucosidesIsoflavonesProtein Serine-Threonine KinasesScaffold Protein ILK

Identifiers

PMID26346982
PMCPMC4562353
OpenAlexW1890471463

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.